Kellner Group Isses Letter to Stockholders of AIM ImmunoTech

TipRanksNov 26 07:11 ET

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

BusinesswireNov 25 08:00 ET

Insider Purchase: CEO & President of $AIM (AIM) Buys 60,110 Shares

Quiver QuantitativeNov 20 13:00 ET

Express News | AIM ImmunoTech Form4 Filing Shows CEO And President Thomas K Equels Bought 60,110 Shares At An Average Price Of $0.18/Share

BenzingaNov 20 12:55 ET

AIM ImmunoTech Announces Data Pubished on Part 1 Study on Ampligen

TipRanksNov 19 08:11 ET

AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer

BenzingaNov 19 08:02 ET